scholarly journals Early toxicity predicts long-term survival in high-grade glioma

2011 ◽  
Vol 104 (9) ◽  
pp. 1365-1371 ◽  
Author(s):  
Y R Lawrence ◽  
M Wang ◽  
A P Dicker ◽  
D Andrews ◽  
W J Curran ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival ◽  
Early Toxicity

Photodynamic therapy of high grade glioma – long term survival

2005 ◽  
Vol 12 (4) ◽  
pp. 389-398 ◽  
Author(s):  
Stanley S. Stylli ◽  
Andrew H. Kaye ◽  
Lachlan MacGregor ◽  
Megan Howes ◽  
Priya Rajendra
Keyword(s):  
Photodynamic Therapy ◽  
High Grade Glioma ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival

scholarly journals HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

Gene Therapy ◽  
2004 ◽  
Vol 11 (22) ◽  
pp. 1648-1658 ◽  
Author(s):  
S Harrow ◽  
V Papanastassiou ◽  
J Harland ◽  
R Mabbs ◽  
R Petty ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Safety Data ◽  
High Grade Glioma ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival ◽  
The Brain

scholarly journals MBRS-31. COMBINING IRRADIATION AND ANTI-CD47 TO ENHANCE THE TREATMENT OF GROUP 3 MEDULLOBLASTOMA

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii403-iii404
Author(s):  
Osama Youssef ◽  
Jeff Turner ◽  
Gongping He ◽  
Jingye Yang ◽  
Samuel Cheshier
Keyword(s):  
Pediatric Brain Tumor ◽  
High Grade Glioma ◽  
High Grade ◽  
Molecular Subgroup ◽  
Term Survival ◽  
Long Term Survival ◽  
Human Neural Stem Cells ◽  
Group 3

Abstract Medulloblastoma (MB) is the most common malignant primary pediatric brain tumor. The Group 3 molecular subgroup of Medulloblastoma (Group 3 MB) is the deadliest with only 30% long term survival. Irradiation for Group 3 Medulloblastoma is required for long term survival of children. Methods to enhance the effect of irradiation against Group 3 MB are an active area of investigation. Immunotherapy using the anti-CD47 treatment has shown promise in treating Group 3 MB. We recently demonstrated that irradiation significantly enhanced anti-CD47-mediated phagocytosis of high-grade glioma cells in vitro. Furthermore, mice engrafted with human high-grade glioma that received anti-CD47 combined with irradiation showed a significant increase in the survival rate and a significant decrease in tumor growth than those that received a single treatment. We have now extended these studies to demonstrate the enhancement of anti-CD47-dependent phagocytosis of human Group 3 MB with irradiation. We also analyzed normal human neural stem cells exposed to the same treatments to assess for the potential toxicity that uniquely exists with this treatment combination.

scholarly journals THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii472-iii472
Author(s):  
Angela Richardson ◽  
Sara Collins ◽  
Akihito Inagaki ◽  
Valerie Armstrong ◽  
David Robbins ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Clinical Trials ◽  
Median Survival ◽  
High Grade Glioma ◽  
Phase Iii ◽  
Post Inoculation ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival

Abstract Toca 511, a clinical-stage tumor-selective retroviral replicating vector (RRV), encodes optimized yeast cytosine deaminase (CD), which converts the prodrug 5-fluorocytosine (5-FC) to the active drug 5-fluorouracil (5-FU) within infected cancer cells. In preclinical models of intracerebral glioblastoma, 5-FU generated locally by Toca 511 (RRV-CD) prodrug activator gene therapy has also been shown to kill immunosuppressive myeloid cells in the tumor microenvironment, leading to anti-cancer immune activation and long-term survival. Early-phase clinical trials of Toca 511 in recurrent high-grade glioma showed highly promising evidence of therapeutic benefit, leading to a Phase III trial completed in late 2019 (n=400 patients, randomized 1:1 vs. standard chemotherapy), which appeared to show negative results overall. However, additional analysis showed possible efficacy in prespecified subgroups, and further clinical investigation is being pursued. In preclinical studies, we have also evaluated RRV for use in medulloblastoma, the most common malignant tumor of the pediatric nervous system. Both established and primary human medulloblastoma cell lines supported efficient RRV replication in vitro, with spread to >90% of cells by day 10 post-inoculation, and RRV-CD-transduced medulloblastoma cells showed significant dose-dependent reduction of viability upon exposure to 5-FC, compared to controls. In an intracerebellar HDMB03 medulloblastoma model, RRV-CD-treated mice exhibited long-term survival while on sequential cycles of 5-FC prodrug, until prodrug treatment was stopped, after which 25% long-term survival was observed (median survival 110 days) as compared to controls (median survival 28 days, 100% lethality) (p=0.00007). These results support further evaluation of RRV-mediated prodrug activator gene therapy for pediatric brain tumors.

scholarly journals Long-term survival of a child with a high-grade glioma with novel molecular features

2021 ◽  
Vol 14 (10) ◽  
pp. e246423
Author(s):  
Jason W Adams ◽  
Denise Malicki ◽  
Michael Levy ◽  
John Ross Crawford
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival ◽  
Molecular Features

scholarly journals PCN65 - LONG- TERM SURVIVAL AMONG PATIENTS WITH HIGH-GRADE GLIOMA TREATED WITH NIMOTUZUMAB

2018 ◽  
Vol 21 ◽  
pp. S25
Author(s):  
L. Sanchez ◽  
P. Lorenzo-Luaces ◽  
C. Viada Gonzalez
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document